Webinar schedule
Register now for our upcoming educational webinar sessions
Current Status of Radiopharmaceutical Therapies in Prostate Cancer and Building a Sustainable Future for Theranostics
In this session we will:
- Review current indications for radiopharmaceutical based therapies in prostate cancer
- Review recent trial data for Lu177-PSMA and radium 223
- Discuss future multi-disciplinary opportunities for theranostics
Monday, November 11
3:00p.m ET | VOICE-A CE Credit
Presented by: Phillip J. Koo, MD | Chief of Diagnostic Imaging, Banner MD Anderson Cancer Center
Sponsored by: Cardinal Health Nuclear & Precision Health Solutions
Register
Diving Deeper into 68Ga-PSMA-11: Diagnostic and Therapeutic Applications
This presentation will provide a brief overview of Ga68-PSMA-11. Additionally, time will be spent discussing the utility of Ga68 PSMA imaging, potential avenues for future growth and the development of therapeutic agents targeting PSMA. The goal of this presentation is to ultimately provide a comprehensive yet concise overview of the Ga68-PSMA-11 radiopharmaceutical.
- Examine chemical structure, mechanism of action, and production of 68Ga-PSMA-11.
- Discuss patient procedure and clinical workflow.
- Review 68Ga-PSMA-11 utility in staging, recurrence, and therapy planning.
Tuesday, November 12
Noon ET | VOICE-A CE Credit
Presented by: Melissa Snody BS, CNMT | Director - Clinical Theranostics at Telix Pharmaceuticals Limited
Sponsored by: Telix Pharmaceuticals Limited
Register
The Workshop on Imaging with Vizamyl™ (Flutemetalmol F18 injection)
The objectives of the course are:
- Introduction
- Module 1: Brain Anatomy
- Module 2: Patient Preparation, Injection, Acquisition, and Processing
- Module 3: Image Orientation and Display
Tuesday, November 12
3:00p.m ET | VOICE-A CE Credit
Presented by: Jodi Hawkins, CNMT | Clinical Applications Specialist
Sponsored by: GE Healthcare
Register
Radiation Safety considerations for Theranostics products
In this session we will provide a comprehensive overview of radiation safety considerations for establishing and maintaining Theranostics programs, including:
- RAM license and radiation safety program considerations
- Shielding and site planning
- Training required
- Dose calibrator settings and how to operate and calibrate
- Written directives and safe administration of radioactive materials
- USNRC guidelines for administration and patient release
- Emergency procedures
- Other special considerations
Wednesday, November 13
Noon ET | VOICE-A CE Credit
Presented by: Hamid Khosravi, M.Sc., Ph.D., MCCPM, CRPA(R) | Lead Medical & Health Physicist, RSO
Sponsored by: Cardinal Health Nuclear & Precision Health Solutions
Register
Elevating Our Practice – Keeping Patients Safe in the Theranostics Era
Recent advances in theranostics, particularly therapeutic nuclear medicine, warrant reinforcement and awareness of practices that improve patient safety.
Emphasizing the role of bar code verification, electronic order transmission, effective communication, and appropriate management of events, create an environment that help all stakeholders support caregivers and ultimately patients.
In this session we will summarize techniques and characteristics of communication used to relay information related to patient care and elements of healthcare cultures that support patient care. We will also define and describe the influence of cognitive biases in healthcare decision making.
Wednesday, November 13
3:00p.m ET | VOICE-A CE Credit
Presented by: Andrew Brown, PharmD, RPh, BCNP | Nuclear Regulatory Manager and
Kristin Watson Swann, MS, PharmD, BCNP | Nuclear Regulatory Manager
Sponsored by: Cardinal Health Nuclear & Precision Health Solutions
Register
Clinicaltrials.gov dissected – a review of nuclear medicine clinical trials
Research and investment are driving nuclear medicine industry growth. The global nuclear medicine industry is projected to grow from $6B in 2021 to $16B in 2027 (Source: MedRays Intel).
This growth is being driven by newer diagnostic and therapeutic drugs across more clinical indications.
In this session we will review an analysis of the ClinicalTrials.gov database to learn how a portion of diagnostic and therapeutic trials become FDA-approved theranostics, the key isotopes being studied now, and the types of trials likely to release data soon.
Thursday, November 14
Noon ET | VOICE-A CE Credit
Presented by: Becca Segrest, PharmD, ANP | Nuclear Pharmacy Manager
Sponsored by: Cardinal Health Nuclear & Precision Health Solutions
Register
Understanding Neuroendocrine Tumors: Advances in Diagnosis and Treatment
In this session we will examine Neuroendocrine Tumor (NETs) disease, including incidence and prevalence, diagnostic and treatment algorithms, and therapy protocols.
Thursday, November 14
3:00p.m ET | VOICE-A CE Credit
Presented by: Stephanie Hoffman, PharmD | Operations Director
Sponsored by: Cardinal Health Nuclear & Precision Health Solutions
Register
Form title
Learn more about nuclear theranostics at cardinalhealth.com/theranostics
Theranostics Week webinars are for educational purposes only and not intended as legal, compliance, medical or business advice. Cardinal Health disclaims any and all warranties expressed or implied regarding the information provided as part of these webinars or any other webinar offered by Cardinal Health. Each webinar participant remains solely responsible for all compliance and legal requirements applicable to such participant’s own activities. Health care providers are responsible for all medical decisions regarding the use of any drug products with their patients.
**Cardinal Health provided CE courses are approved by the Society of Nuclear Medicine and Molecular Imaging-Technologists Section VOICE – Category A. Valid for both ARRT and NMTCB continuing education requirements for renewal of registration certificates.
© 2024 Cardinal Health. All Rights Reserved. CARDINAL HEALTH, the CARDINAL HEALTH LOGO, and ESSENTIAL TO CARE are trademarks of Cardinal Health and may be registered in the US and/or in other countries. Patent cardinalhealth.com/patents.

